Arrhythmias - Pipeline Review, H1 2018

  • ID: 4464778
  • Report
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cynata Therapeutics Ltd
  • Gilead Sciences Inc
  • OMEICOS Therapeutics GmbH
  • Ono Pharmaceutical Co Ltd
  • Orion Corporation
  • SignPath Pharma Inc
  • MORE
Arrhythmias - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H1 2018, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cynata Therapeutics Ltd
  • Gilead Sciences Inc
  • OMEICOS Therapeutics GmbH
  • Ono Pharmaceutical Co Ltd
  • Orion Corporation
  • SignPath Pharma Inc
  • MORE
Introduction

The Publisher's Report Coverage

Arrhythmias - Overview

Arrhythmias - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Arrhythmias - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Arrhythmias - Companies Involved in Therapeutics Development

Cynata Therapeutics Ltd

Gilead Sciences Inc

LATITUDE Pharmaceuticals Inc

Les Laboratoires Servier SAS

OMEICOS Therapeutics GmbH

Ono Pharmaceutical Co Ltd

Orion Corporation

SignPath Pharma Inc

Arrhythmias - Drug Profiles

amiodarone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Activate hERG1 for Arrhythmias - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efsevin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EU-8120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-967 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KN-93 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landiolol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORM-10103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RyR2 for Heart Failure and Arrhythmias - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target FKBP1A for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPP-4040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cardiovacular Diseases and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Arrhythmias - Dormant Projects

Arrhythmias - Discontinued Products

Arrhythmias - Product Development Milestones

Featured News & Press Releases

Sep 27, 2017: U.S. Patent Granted for Cynata Cymerus Technology

Sep 05, 2017: Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Arrhythmias, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Arrhythmias - Pipeline by Cynata Therapeutics Ltd, H1 2018

Arrhythmias - Pipeline by Gilead Sciences Inc, H1 2018

Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2018

Arrhythmias - Pipeline by Les Laboratoires Servier SAS, H1 2018

Arrhythmias - Pipeline by OMEICOS Therapeutics GmbH, H1 2018

Arrhythmias - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Arrhythmias - Pipeline by Orion Corporation, H1 2018

Arrhythmias - Pipeline by SignPath Pharma Inc, H1 2018

Arrhythmias - Dormant Projects, H1 2018

Arrhythmias - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Arrhythmias, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Cynata Therapeutics Ltd
  • Gilead Sciences Inc
  • LATITUDE Pharmaceuticals Inc
  • Les Laboratoires Servier SAS
  • OMEICOS Therapeutics GmbH
  • Ono Pharmaceutical Co Ltd
  • Orion Corporation
  • SignPath Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll